Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)

Baum talks about potential label expansions for Sutent and the early stage pipeline. Plus, Oncology Commercial Head Ayers weighs in with Pfizer’s take on licensing and acquisitions in the therapeutic area.